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Background: Coenzyme Q10 is an essential cofactor in the respiratory chain and serves in its reduced form,
ubiquinol, as a potent antioxidant. Studies in vitro and in vivo provide evidence that ubiquinol reduces
inflammatory processes via gene expression. Here we investigate the putative link between expression and DNA
methylation of ubiquinol sensitive genes in monocytes obtained from human volunteers supplemented with
150 mg/ day ubiquinol for 14 days.
Findings: Ubiquinol decreases the expression of the pro-inflammatory chemokine (C-X-C motif) ligand 2 gene
(CXCL2) more than 10-fold. Bisulfite-/ MALDI-TOF-based analysis of regulatory regions of the CXCL2 gene identified
six adjacent CpG islands which showed a 3.4-fold decrease of methylation status after ubiquinol supplementation.
This effect seems to be rather gene specific, because ubiquinol reduced the expression of two other
pro-inflammatory genes (PMAIP1, MMD) without changing the methylation pattern of the respective gene.
Conclusion: In conclusion, ubiquinol decreases monocytic expression and DNA methylation of the
pro-inflammatory CXCL2 gene in humans. Current Controlled Trials ISRCTN26780329.
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Coenzyme Q10 (CoQ10) is a key component of the mito-
chondrial respiratory chain where it is mainly known for
its role in oxidative phosphorylation. The reduced form
of CoQ10, ubiquinol, serves as a potent antioxidant in
mitochondria, lipid membranes and plasma lipoproteins
[1,2] as well as a regenerator of other lipid soluble anti-
oxidants (e.g. vitamin E) [3,4]. Several studies in vitro
[5-7], in SAMP1 mice [8] and in humans [9] indicate
that ubiquinol is involved in inflammatory processes
and lipid metabolism via gene expression.
Gene expression as well as DNA methylation pro-
cesses are affected by various dietary supplements and
food nutrients [10-13]. Furthermore, DNA methylation
is one of the epigenetic modifications that per se is able
to determine the gene expression by regulating the chro-
matin organization [10,14]. During methylation of* Correspondence: sek@molprev.uni-kiel.de
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reproduction in any medium, provided the ormammalian DNA a methyl group is attached at
the 5-position of the cytosine residue within the
cytosine-guanine dinucleotides (CpG) resulting in the
formation of 5-methylcytosine, which is designated as
the fifth base of DNA [15]. Although most genomic
DNA in mammals is deficient in CpG sites, clusters of
CpG dinucleotides (CpG islands) were described to be
primarily located at promoter regions of genes [16].
Here we investigated the effect of ubiquinol on the ex-
pression and methylation of CpG island promoter
regions of pro-inflammatory genes in humans.
Materials and methods
Participants and study design
Sample characteristics of subjects and study design have
been described lately [9]. Briefly: fifty-three healthy male
volunteers, 21–48 years of age, received 150 mg of the
reduced form of CoQ10 (Q10H2, ubiquinol, KANEKA
Corporation, Japan) daily in form of three capsules with
each principal meal for 14 days. Fasting blood samples
were taken before (T0) and after (T14) supplementation.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Normalized steady-state mRNA expression levels
(AU) of the CXCL2, PMAIP1 and MMD gene in monocytes
of human volunteers before (T0) and after (T14)
supplementation with ubiquinol
Gene T0 T14 Fold change
(T0 vs. T14)
PMAIP1 1271± 35 578 ± 106 -2,2
MMD 147 ± 30 85 ± 19 -1,7
CXCL2 1150± 865 93 ± 30 -12,4
T0, expression levels before supplementation (baseline); T14, expression levels
after a 14 day supplementation period with 150 mg/ d ubiquinol; fold change,
relative change from time point T0 to T14; AU, arbitrary units; Data are given as
mean ± SEM.
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of 24.1 ± 2.5 kg/m2, no history of gastrointestinal, hep-
atic, cardiovascular or renal diseases, a habit of non- or
occasional smoking and maintenance of usual nutrition
habits. The study was approved by the ethics committee
of the Medical Faculty of Kiel University, Germany, and
was conformed to Helsinki Declaration. All volunteers
gave written informed consent.
Microarray-based gene expression analysis and qRT-PCR
Microarray experiment using the Affymetrix human
genome U133 plus 2.0 GeneChipW were performed as
described previously [5] with RNA samples from CD14-
positive monocytes obtained from three volunteers
before (T0) and after (T14) supplementation with ubiqui-
nol. Based on microarray data, expression levels of
selected genes including the CXCL2, MMD and
PMAIP1 gene were verified by real-time qRT-PCR. Pri-
mer sequences for real-time qRT-PCR experiments were
designed with Primer ExpressW Software 3.0 (Applied
Biosystems, Darmstadt, Germany). Primer pairs were
obtained from MWG Biotech AG (Ebersberg, Germany).
cDNA synthesis with subsequent PCR amplification pro-
cedure has been described before [9].
Methylation analysis of genomic regions of CXCL2, MMD
and PMAIP1 gene
The presence of CpG islands within the CXCL2, MMD
and PMAIP1 genes was predicted using the European
Molecular Biology Open Software Suite CpGplot, re-
spectively. Quantitative methylation analysis was per-
formed on the MassARRAYW system (Sequenom,
Hamburg, Germany) at BioGlobe (Hamburg, Germany)
applying the MassCLEAVETM (hMC) biochemistry after
bisulfit treatment of DNA samples and MALDI-TOF
mass spectrometry for analyte detection. All reactions
were performed according to the standard protocols
recommended by the supplier. Genomic DNA was
extracted from human monocytes obtained from five
volunteers (H1/H1_1 to H5/H5_1) before (T0, H1-H5)
and after (T14, H1_1-H5_5) using the DNeasy Tissue Kit
(Quiagen). Analysis was carried out from both, forward
and reverse strand.
The protocol starts with a bisulfit treatment of pro-
vided genomic DNA sample, which converts native
cytosine (“C”) nucleotides into uracil (“U”), whereas 5-
methyl-protected cytosine residues remain as “C”. The
resulting artificial sequence variation is conserved during
PCR amplification using methylation independent pri-
mers. One primer for each PCR is tagged with T7 RNA
polymerase promoter sequence facilitating the trans-
formation of double stranded PCR product into single
stranded RNA together with a second level of amplifica-
tion. The in vitro transcription product is “U-specific”cleaved with RNase A. The generated fragments repre-
sent unique portions of the amplified region of interest
and are displayed based on their molecular weight in the
mass spectrum, which is acquired after sample condi-
tioning with a MassARRAYW Analyzer Compact. Auto-




Ubiquinol supplementation reduces the expression of low
and high abundant mRNA steady-state levels of pro-
inflammatory genes in human monocytes
Several studies in vitro and in rodents indicate that Co-
enzyme Q10 or rather its reduced form, ubiquinol,
reduces inflammatory processes via gene expression. To
study the putative link between ubiquinol dependent
gene expression and DNA methylation we used probes
from our human study [9]. In this study, we found a sig-
nificant decrease of LDL-cholesterol and erythropoiesis
after a 14 day supplementation period with 150 mg/ day
ubiquinol. Microarray-based gene expression analysis
and qRT-PCR verification of selected genes identified
272 genes regulated by ubiquinol supplementation in
monocytes. This gene list was used to select pro-
inflammatory genes which differ in their expression
levels at baseline (T0) and showed markedly differences
in ubiquinol dependent regulation. Therefore, three
genes encoding the chemokine (C-X-C motif ) ligand 2
(CXCL2), the phorbol-12-myristate-13-acetate-induced
protein 1 (PMAIP1) and the monocyte to macrophage
differentiation-associated protein (MMD) were selected.
CXCL2 as well as PMAIP1 and MMD are involved in
differentiation processes of blood monocytes to macro-
phages [17-20]. Furthermore, CXCL2 and PMAIP1 are
key players in apoptosis induction and inflammatory
responses, respectively [21-23]. The MMD gene is highly
expressed in mature macrophages but its exact biological
function is not clear so far [24]. As shown in Table 1,
PMAIP1 and CXCL2 showed about 8.7 to 7.9-fold
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(T0) in human monocytes. Ubiquinol supplementation
leads to a down regulation of the low expressing MMD
gene by a factor of 1.7. The expression of the high abun-
dant transcript of the PMAIP gene is 2.2-fold reduced
by ubiquinol. Remarkably, ubiquinol decreases the ex-
pression of the high expressing CXCL2 gene more than
10-fold. Together, ubiquinol reduces the expression of
the pro-inflammatory genes CXCL2, PMAIP1 and
MMD.
Ubiquinol supplementation reduces the methylation status
of six adjacent CpG islands within the promoter of the
CXCL2 gene
There is evidence that difference in gene expression
correlates with CpG island variation [25]. In order to
evaluate whether the ubiquinol dependent reduction in
the expression of the CXCL2, PMAIP1 and MMD gene
are linked to variation in methylation patterns, bisulfit-
based and matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry was
used for analysing CpG islands within promoter regions
of the respective genes. As shown in Table 2 and
Figure 1A/ Additional file 1: Figure S1A/ Additional file
2: Figure S2A, we analysed in total 656 CpG islands
which covered the promoter regions and the adjacent
exon 1 of the CXCL2 (146 CpG islands), PMAIP1 (347)
and MMD (163) gene. There was only weak methylation
detected in the analysed CpG islands of the genes
PMAIP1 and MMD before and after supplementationTable 2 Position, length and number of CpG islands of amplic
human CXCL2, PMAIP1 and MMD gene
start end length CpGs le
gene/amplicon
PMAIP1_amp01 f 3 565 563 57 ATTGTT
PMAIP1_amp02 f 485 1068 584 49 TTTTAGTA
PMAIP1_amp03 f 1113 1529 417 13 AGGGTTT
PMAIP1_amp07 f -23 565 587 57 TTTGGG
PMAIP1_amp04 r 3 512 510 53 AATAGTT
PMAIP1_amp05 r 374 954 581 53 AGGAGG
PMAIP1_amp06 r 930 1481 552 22 TTGTTATTA
PMAIP1_amp08 r -9 399 409 43 TTGTTTA
MMD_amp01 f 236 986 751 81 AGGTAG
MMD_amp02 r 274 1015 742 82 TAGGGA
CXCL2_amp01 f 2 427 426 30 AGGATSGS
CXCL2_amp02 f 228 780 553 48 GGGGTAGA
CXCL2_amp03 r 45 491 447 34 GAGGAG
CXCL2_amp04 r 399 794 396 34 GATGTT
The start and end positions of amplicons refer to the genomic regions as illustrated
Additional file 2: Figure S2 (MMD). Primer sequences shown in 5´ to 3´ direction are
from the original genomic target by exchanging each “C” with “T”. f, forward directwith ubiquinol (Additional file 1: Figure S1B-H, Additional
file 2: Figure S2B/C). Most CpG islands of the CXCL2 gene
were also unaffected by ubiquinol (Figure 1B/D/E). As
shown in Figure 1C, the methylation status of six adjacent
CpG islands (39 to 44) was reduced under ubiquinol treat-
ment. Methylation pattern of CpG islands which are
located in close proximity to this region showed no alter-
ation before and after ubiquinol supplementation. Quanti-
tative analysis revealed that ubiquinol reduced the
methylation of CpG islands 39–44 (Figure 2) of the CXCL2
gene by a factor of 3.4.
The effect of ubiquinol on DNA methylation seems to be
rather gene specific and might depend on the extent of
ubiquinol induced alteration of gene expression
Our study provides a first hint towards a modifying ef-
fect of ubiquinol on DNA methylation in humans. This
effect is in line with another human study demonstrating
that a supplementation with a mixture of CoQ10, niacin
and riboflavin reduces DNA methylation of the tumor
suppressor gene RASSF1A in breast cancer patients
undergoing tamoxifen therapy [26]. Moreover, literature
indicates that global methylation patterns are affected by
several other dietary supplements and micronutrients
[27-32]. The effect of ubiquinol on DNA methylation
seems be rather gene specific because we identified two
genes (PMAIP1, MMD) which are regulated by ubiqui-
nol without changing DNA methylation. A recent
SAMP-mice study from our group [33] found that ubi-
quinol alters hepatic expression of PPARα target genesons covering the analysed genomic regions of the















in Figure 1 (CXCL2 gene) and Additional file 1: Figure S1 (PMAIP1) and
complementary to sequences obtained after bisulfite treatment and differ
ion of the amplicon; r, reverse direction of the amplicon.
Figure 1 (See legend on next page.)
Fischer et al. BMC Research Notes 2012, 5:540 Page 4 of 7
http://www.biomedcentral.com/1756-0500/5/540
(See figure on previous page.)
Figure 1 Position of amplicons within the analysed genomic region (A) and methylation status of CpG islands (B-E) of the human
CXCL2 gene. A, The genomic region of the CXCL2 gene is located from −365 to +450 relative to the gene start. This refers to position
74964548–74965362 of the NCBI’s human genome build 37.1. The gene is shown in its transcripted orientation and locates on the sense strand
of chromosome 4. Colors illustrate position of the gene (blue), mRNA (green), region for amplicon design (orange), amplicons (yellow) and
annotated (Ensembl) regulatory region (pink). B-E, Colored dots indicate the methylation ratio (%) at each analyzed CpG-unit within each
amplicon. Samples are indicated as H-1 to H-5 (time point T0) and H-1_1 to H-5_1 (T14). Base count (upper ruler scale) and CpG-site numbering
(lower ruler scale) refers to the analyzed strand in 5’!3’ orientation of the analyzed amplicon sequence. Sample “nc_001” represents the reaction
negative control (water) and “con42” a control DNA.
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gene promoters.
The effect of ubiquinol on DNA methylation might be
linked to the extent of ubiquinol dependent alteration of
gene expression. In the case of the CXCL2 gene, ubiqui-
nol reduces its expression more than 10-fold accompan-
ied by a reduced methylation status within certain CpG
islands. This finding seems to be contradictory to com-
mon models of gene expression, because increased DNA
methylation of a gene leads to reduced expression levels
[34], whereas demethylation correlates with the tran-
scription of the gene [35]. On the other hand there is
evidence, especially in cancer cells, that DNA methyla-
tion status does not correlate with gene expression
[36,37]. However, the mechanism regarding effects of
ubiquinol on DNA methylation and expression remains
unclear and has to be studied in the future. The reduced
expression of pro-inflammatory genes under ubiquinol
supplementation supports recent findings from our lab
[5,6,8,9,38-41] and other groups [42,43] suggesting that
CoQ10 displays anti-inflammatory properties. As a sum-
mary, we found in a human intervention study that ubi-
quinol decreases expression and DNA methylation of
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Figure 2 Methylation status of CpG islands of the CXCL2 gene
in monocytes of human volunteers before (T0) and after (T14) a
14 day supplementation period with ubiquinol. The extent of
methylation (%, mean± SD) of CpG islands 33, 39–44 and 45 within
amplicon 2 of the CXCL2 gene (see Figure 1C) is shown.Further studies will be necessary to investigate the
mechanistic link between ubiquinol dependent gene ex-
pression, DNA methylation and inflammation.Additional files
Additional file 1: Figure S1. Position of amplicons within the analysed
genomic region (A) and methylation status of CpG islands (B-H) of the
human PMAIP gene. A, The genomic region of the PMAIP gene is
located from −390 to +1153 relative to the gene start. This refers to
position 57566802–57568344 of the NCBI’s human genome build 37.1.
The gene is shown in its transcripted orientation and locates on the
sense strand of chromosome 18. Colors illustrate position of the gene
(blue), mRNA (green), region for amplicon design (orange), amplicons
(yellow) and annotated (Ensembl) regulatory region (pink). B-H, Colored
dots indicate the methylation ratio (%) at each analyzed CpG-unit within
each amplicon. Samples are indicated as H-1 to H-5 (time point T0) and
H-1_1 to H-5_1 (T14). Base count (upper ruler scale) and CpG-site
numbering (lower ruler scale) refers to the analyzed strand in 5’!3’
orientation of the analyzed amplicon sequence. Sample “nc_001”
represents the reaction negative control (water) and “con42” a control
DNA.
Additional file 2: Figure S2. Position of amplicons with in the analysed
genomic region (A) and methylation status of CpG islands (B, C) of the
human MMD gene. A, The genomic region of the MMD gene is located
from −564 to +470 relative to the gene start. This refers to position
53498872–53499905 of the NCBI’s human genome build 37.1. The gene
is shown in its transcripted orientation and locates on the sense strand of
chromosome 17. Colors illustrate position of the gene (blue), mRNA
(green), region for amplicon design (orange), amplicons (yellow) and
annotated (Ensembl) regulatory region (pink). B and C, Colored dots
indicate the methylation ratio (%) at each analyzed CpG-unit within each
amplicon. Samples are indicated as H-1 to H-5 (time point T0) and H-1_1
to H-5_1 (T14). Base count (upper ruler scale) and CpG-site numbering
(lower ruler scale) refers to the analyzed strand in 5’!3’ orientation of
the analyzed amplicon sequence. Sample “nc_001” represents the
reaction negative control (water) and “con42” a control DNA.Competing interest
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